Discovery of Novel Nav1.7-Selective Inhibitors with the 1H-Indole-3-Propionamide Scaffold for Effective Pain Relief
Nav1.7 is considered a promising target for developing next-generation analgesic drugs, given its critical role in human pain pathologies. Although most reported inhibitors with strong in vitro activity and high selectivity share the aryl sulfonamide scaffold, they failed to demonstrate marked clini...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
American Association for the Advancement of Science (AAAS)
2025-01-01
|
| Series: | Research |
| Online Access: | https://spj.science.org/doi/10.34133/research.0599 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832582848230457344 |
|---|---|
| author | Gaoang Wang Hang Wu Yingying Wang Xiangying Liu Shuijiao Peng Wenxing Wang Meijing Wu Yifei Liu Ercheng Wang Zhe Wang Lei Xu Xiaojian Wang Wei Yang Haiyi Chen Xi Zhou Tingjun Hou |
| author_facet | Gaoang Wang Hang Wu Yingying Wang Xiangying Liu Shuijiao Peng Wenxing Wang Meijing Wu Yifei Liu Ercheng Wang Zhe Wang Lei Xu Xiaojian Wang Wei Yang Haiyi Chen Xi Zhou Tingjun Hou |
| author_sort | Gaoang Wang |
| collection | DOAJ |
| description | Nav1.7 is considered a promising target for developing next-generation analgesic drugs, given its critical role in human pain pathologies. Although most reported inhibitors with strong in vitro activity and high selectivity share the aryl sulfonamide scaffold, they failed to demonstrate marked clinical efficacy. Therefore, exploring new Nav1.7-selective antagonists is quite urgent to the development of next-generation analgesic drugs. Here, we report a highly effective 1H-indole-3-propionamide inhibitor, WN2, identified through an integrated drug discovery strategy. Notably, the structure of WN2 is quite different from previously reported aryl sulfonamide inhibitors. Molecular dynamics simulations and experimental findings reveal that the R configuration of WN2 (WN2-R) is the preferred form (IC50 = 24.7 ± 9.4 nM) within the VSDIV pocket of Nav1.7. WN2-R exhibits impressive analgesic effects in acute and chronic inflammatory pain, as well as neuropathic pain models in mice. Additionally, it displays favorable subtype selectivity and positive drug safety in acute toxicity studies. Pharmacokinetic studies indicate that WN2-R has high bioavailability (F = 20.29%), highlighting its considerable potential for drug development. Our study establishes WN2-R as a novel Nav1.7-selective inhibitor with a unique structural scaffold, offering a promising candidate for the next generation of analgesic drugs. |
| format | Article |
| id | doaj-art-8be780197dbb4ce3956044e530db57d7 |
| institution | Kabale University |
| issn | 2639-5274 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | American Association for the Advancement of Science (AAAS) |
| record_format | Article |
| series | Research |
| spelling | doaj-art-8be780197dbb4ce3956044e530db57d72025-01-29T08:00:22ZengAmerican Association for the Advancement of Science (AAAS)Research2639-52742025-01-01810.34133/research.0599Discovery of Novel Nav1.7-Selective Inhibitors with the 1H-Indole-3-Propionamide Scaffold for Effective Pain ReliefGaoang Wang0Hang Wu1Yingying Wang2Xiangying Liu3Shuijiao Peng4Wenxing Wang5Meijing Wu6Yifei Liu7Ercheng Wang8Zhe Wang9Lei Xu10Xiaojian Wang11Wei Yang12Haiyi Chen13Xi Zhou14Tingjun Hou15College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang 310058, China.The National and Local Joint Engineering Laboratory of Animal Peptide Drug Development, College of Life Sciences, and Peptide and Small Molecule Drug R&D Platform, Furong Laboratory, Hunan Normal University, Changsha 410081, Hunan, China.Zhejiang University School of Medicine, Hangzhou 310000, Zhejiang, China.State Key Laboratory of Bioactive Substance and Function of Natural Medicines and Beijing Key Laboratory of Active Substances Discovery and Druggability Evaluation, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.The National and Local Joint Engineering Laboratory of Animal Peptide Drug Development, College of Life Sciences, and Peptide and Small Molecule Drug R&D Platform, Furong Laboratory, Hunan Normal University, Changsha 410081, Hunan, China.The National and Local Joint Engineering Laboratory of Animal Peptide Drug Development, College of Life Sciences, and Peptide and Small Molecule Drug R&D Platform, Furong Laboratory, Hunan Normal University, Changsha 410081, Hunan, China.The National and Local Joint Engineering Laboratory of Animal Peptide Drug Development, College of Life Sciences, and Peptide and Small Molecule Drug R&D Platform, Furong Laboratory, Hunan Normal University, Changsha 410081, Hunan, China.College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang 310058, China.Zhejiang Laboratory, Hangzhou 311100, Zhejiang, China.School of Pharmacy, Hangzhou Normal University, Hangzhou 311121, Zhejiang, China.Institute of Bioinformatics and Medical Engineering, School of Electrical and Information Engineering, Jiangsu University of Technology, Changzhou 213001, Jiangsu, China.State Key Laboratory of Bioactive Substance and Function of Natural Medicines and Beijing Key Laboratory of Active Substances Discovery and Druggability Evaluation, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.Zhejiang University School of Medicine, Hangzhou 310000, Zhejiang, China.College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang 310058, China.The National and Local Joint Engineering Laboratory of Animal Peptide Drug Development, College of Life Sciences, and Peptide and Small Molecule Drug R&D Platform, Furong Laboratory, Hunan Normal University, Changsha 410081, Hunan, China.College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang 310058, China.Nav1.7 is considered a promising target for developing next-generation analgesic drugs, given its critical role in human pain pathologies. Although most reported inhibitors with strong in vitro activity and high selectivity share the aryl sulfonamide scaffold, they failed to demonstrate marked clinical efficacy. Therefore, exploring new Nav1.7-selective antagonists is quite urgent to the development of next-generation analgesic drugs. Here, we report a highly effective 1H-indole-3-propionamide inhibitor, WN2, identified through an integrated drug discovery strategy. Notably, the structure of WN2 is quite different from previously reported aryl sulfonamide inhibitors. Molecular dynamics simulations and experimental findings reveal that the R configuration of WN2 (WN2-R) is the preferred form (IC50 = 24.7 ± 9.4 nM) within the VSDIV pocket of Nav1.7. WN2-R exhibits impressive analgesic effects in acute and chronic inflammatory pain, as well as neuropathic pain models in mice. Additionally, it displays favorable subtype selectivity and positive drug safety in acute toxicity studies. Pharmacokinetic studies indicate that WN2-R has high bioavailability (F = 20.29%), highlighting its considerable potential for drug development. Our study establishes WN2-R as a novel Nav1.7-selective inhibitor with a unique structural scaffold, offering a promising candidate for the next generation of analgesic drugs.https://spj.science.org/doi/10.34133/research.0599 |
| spellingShingle | Gaoang Wang Hang Wu Yingying Wang Xiangying Liu Shuijiao Peng Wenxing Wang Meijing Wu Yifei Liu Ercheng Wang Zhe Wang Lei Xu Xiaojian Wang Wei Yang Haiyi Chen Xi Zhou Tingjun Hou Discovery of Novel Nav1.7-Selective Inhibitors with the 1H-Indole-3-Propionamide Scaffold for Effective Pain Relief Research |
| title | Discovery of Novel Nav1.7-Selective Inhibitors with the 1H-Indole-3-Propionamide Scaffold for Effective Pain Relief |
| title_full | Discovery of Novel Nav1.7-Selective Inhibitors with the 1H-Indole-3-Propionamide Scaffold for Effective Pain Relief |
| title_fullStr | Discovery of Novel Nav1.7-Selective Inhibitors with the 1H-Indole-3-Propionamide Scaffold for Effective Pain Relief |
| title_full_unstemmed | Discovery of Novel Nav1.7-Selective Inhibitors with the 1H-Indole-3-Propionamide Scaffold for Effective Pain Relief |
| title_short | Discovery of Novel Nav1.7-Selective Inhibitors with the 1H-Indole-3-Propionamide Scaffold for Effective Pain Relief |
| title_sort | discovery of novel nav1 7 selective inhibitors with the 1h indole 3 propionamide scaffold for effective pain relief |
| url | https://spj.science.org/doi/10.34133/research.0599 |
| work_keys_str_mv | AT gaoangwang discoveryofnovelnav17selectiveinhibitorswiththe1hindole3propionamidescaffoldforeffectivepainrelief AT hangwu discoveryofnovelnav17selectiveinhibitorswiththe1hindole3propionamidescaffoldforeffectivepainrelief AT yingyingwang discoveryofnovelnav17selectiveinhibitorswiththe1hindole3propionamidescaffoldforeffectivepainrelief AT xiangyingliu discoveryofnovelnav17selectiveinhibitorswiththe1hindole3propionamidescaffoldforeffectivepainrelief AT shuijiaopeng discoveryofnovelnav17selectiveinhibitorswiththe1hindole3propionamidescaffoldforeffectivepainrelief AT wenxingwang discoveryofnovelnav17selectiveinhibitorswiththe1hindole3propionamidescaffoldforeffectivepainrelief AT meijingwu discoveryofnovelnav17selectiveinhibitorswiththe1hindole3propionamidescaffoldforeffectivepainrelief AT yifeiliu discoveryofnovelnav17selectiveinhibitorswiththe1hindole3propionamidescaffoldforeffectivepainrelief AT erchengwang discoveryofnovelnav17selectiveinhibitorswiththe1hindole3propionamidescaffoldforeffectivepainrelief AT zhewang discoveryofnovelnav17selectiveinhibitorswiththe1hindole3propionamidescaffoldforeffectivepainrelief AT leixu discoveryofnovelnav17selectiveinhibitorswiththe1hindole3propionamidescaffoldforeffectivepainrelief AT xiaojianwang discoveryofnovelnav17selectiveinhibitorswiththe1hindole3propionamidescaffoldforeffectivepainrelief AT weiyang discoveryofnovelnav17selectiveinhibitorswiththe1hindole3propionamidescaffoldforeffectivepainrelief AT haiyichen discoveryofnovelnav17selectiveinhibitorswiththe1hindole3propionamidescaffoldforeffectivepainrelief AT xizhou discoveryofnovelnav17selectiveinhibitorswiththe1hindole3propionamidescaffoldforeffectivepainrelief AT tingjunhou discoveryofnovelnav17selectiveinhibitorswiththe1hindole3propionamidescaffoldforeffectivepainrelief |